98%
921
2 minutes
20
Alcohol intolerance, characterized by adverse reactions following alcohol consumption, can occur due to interactions between alcohol and certain medications. Despite its clinical significance, evidence for alcohol intolerance induced by commonly prescribed drugs remains limited. This study aimed to identify signals for drug-associated alcohol intolerance using the United States Food and Drug Administration (USFDA) Adverse Event Reporting System (AERS). A disproportionality analysis was conducted on the USFDA AERS spanning the first quarter of 2004 to the second quarter of 2024. Cases were identified using the Preferred Term "alcohol intolerance". Duplicate reports were excluded, and only drugs classified as primary suspects were analyzed. The key disproportionality measures included frequentists (reporting odds ratio [ROR]) and Bayesian methods. Top 10 drugs associated with alcohol intolerance were identified using volcano plot. Subgroup analyses by age and gender were performed, and clinical outcomes were evaluated. Among 29 153 222 reports, 406 cases of drug-associated alcohol intolerance were identified, predominantly in adults aged 18 to 65 years. Multiple drug classes demonstrated significant signals including antimicrobials (metronidazole [ROR: 27.4], cefoperazone [ROR: 290.6]), and ketoconazole [ROR: 27.6]), respiratory medications (salmeterol [ROR: 6], mometasone [ROR: 6], and dupilumab [ROR: 6.1]), and psychoanaleptics (bupropion [ROR: 8.1] and several selective serotonin reuptake inhibitors). The Volcano plot analysis highlighted 10 drugs with particularly strong associations, including cefoperazone, spiramycin, metronidazole, and dupilumab. Outcomes included hospitalization (16%), disability (6.4%), and death (1.7%). This study highlights significant associations between several medications and alcohol intolerance, emphasizing the need for further research to confirm these findings and inform clinical guidelines to optimize patient safety.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204988 | PMC |
http://dx.doi.org/10.1177/00185787251345806 | DOI Listing |
Clin Spine Surg
September 2025
Department of Neurosurgery, Neurosurgery, The Walton Centre NHS Foundation Trust, Lower Lane.
Study Design: Retrospective cohort study.
Objective: To characterise patients admitted to a UK tertiary centre with OPLL over a 10-year period.
Summary Of Background Data: OPLL is a progressive degenerative condition that can lead to myelopathy.
J Hepatol
September 2025
Hepatitis B Foundation & Loma Linda University, USA. Electronic address:
Psychol Violence
May 2025
Department of Psychology, University of Washington, Seattle, WA.
Objective: The I model outlines how factors interact to predict intimate partner violence (IPV) perpetration such as relationship tension, emotion regulation (ER) and distress tolerance difficulties, and alcohol use. Despite the model's emphasis on these factors' synergistic nature (i.e.
View Article and Find Full Text PDFBiomedicines
August 2025
Cardiology Department, Regional General Hospital 'F. Miulli', 70021 Acquaviva delle Fonti, Italy.
: High concentration of plasma low-density lipoprotein cholesterol (LDL-C) is the predominant cause of atherosclerotic cardiovascular disease progression and coronary heart disease. Nutraceutical combination together with a cholesterol-lowering action provides an alternative to pharmacotherapy in patients reporting intolerance to statins and in subjects with low cardiovascular risk. The effects on lipid parameters were evaluated over 6 months for a food supplement containing aqueous extract of and , fenugreek seed extract, water/ethanol extract of artichoke leaf and phytosterols from sunflower seeds (Ritmon Colesystem).
View Article and Find Full Text PDFSci Rep
August 2025
Faculty of Medicine, Department of Parasitology, Assiut University, Assiut, 71515, Egypt.
The intolerable side effects and clinical limitations of current conventional therapies for inflammatory bowel diseases (IBDs), there is a pressing need for alternative treatment options. Helminthes adapt immune responses of their hosts to reduce immune-mediated IBDs. The identification of the mechanism responsible for this beneficial effect on IBDs will provide another feasible approach to treating these diseases.
View Article and Find Full Text PDF